1. Scrip
  2. >>Leadership

Sanofi R&D Chief Zerhouni: How I'm Doing More With Less

 
• By Sten Stovall

Elias Zerhouni says Sanofi's ongoing R&D revamp has produced improved innovative results with controlled spending, in part by emphasizing cutting-edge product development ahead of research.

Elias Zerhouni
Elias Zerhouni, Sanofi’s global R&D head • Source: Sanofi

Sanofi 's head of global research and development Elias Zerhouni feels the outside world – meaning analysts and investors – have yet to fully appreciate the pipeline progress and future promise generated by his ongoing revamp of the French group's R&D process, but he is confident that will soon happen, helped by further expected success developing multi-specific therapies.

A native of Algeria, Zerhouni was appointed to his current position in 2011 by former Sanofi CEO Chris Viehbacher. Remaining in that role under current CEO Olivier Brandicourt, Zerhouni has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.